Cargando…
CytoResc – “CytoSorb” Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial
OBJECTIVES: Approximately 8 - 10 % of COVID-19 patients present with a serious clinical course and need for hospitalization, 8% of hospitalized patients need ICU-treatment. Currently, no causal therapy is available and treatment is purely supportive. The main reason for death in critically ill patie...
Autores principales: | Stockmann, Helena, Keller, Theresa, Büttner, Stefan, Jörres, Achim, Kindgen-Milles, Detlef, Kunz, Julius Valentin, Leebmann, Josef, Spies, Claudia, Träger, Karl, Treskatsch, Sascha, Uhrig, Alexander, Willam, Carsten, Enghard, Philipp, Slowinski, Torsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316574/ https://www.ncbi.nlm.nih.gov/pubmed/32586396 http://dx.doi.org/10.1186/s13063-020-04501-0 |
Ejemplares similares
-
Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption
por: Schneider, Antoine G., et al.
Publicado: (2021) -
CytoSorb-friend or foe!!
por: Pattnaik, Saroj Kumar, et al.
Publicado: (2015) -
Mechanistic Considerations and Pharmacokinetic Implications on Concomitant Drug Administration During CytoSorb Therapy
por: Scheier, Joerg, et al.
Publicado: (2022) -
Impact of CytoSorb® on interleukin-6 in cardiac surgery
por: Geisler, Daniela, et al.
Publicado: (2023) -
Prevention of vasoplegia with CytoSorb in heart failure patients undergoing cardiac surgery (CytoSorb-HF trial): protocol for a randomised controlled trial
por: Papazisi, Olga, et al.
Publicado: (2022)